Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Yajie Chen
Observed name:
Y.D. Chen
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
University of South China
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center,
University of South China
ORCID:
0000-0001-8850-1886
Observed ORCID:
0000-0001-8850-1886
OpenAlex ID:
A5036110682
Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
2025
·
Fan Xia
, Yajie Chen
, et al.
·
Clinical Cancer Research
·
13
An Innovative Model for Diagnosing Lesions in Coronary Angiography Imagery Using an Improved YOLOv4 Model
2025
·
Zhu Chen
, Yajie Chen
, et al.
·
Bioengineering
·
2
An artificial intelligence-enhanced immunomagnetic bead platform for scalable melatonin quantification in heart failure
2026
·
Xiaohan Liu
, Zhu Chen
, et al.
·
Chinese Chemical Letters
·
1
Supplementary Table S1 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
2025
·
Fan Xia
, Yajie Chen
, et al.
·
1
Segment-specific PTV margins for rectal cancer radiotherapy on the MR-Linac: characterization of rectal motion and dosimetric validation
2026
·
Wang Yang
, Lei Yu
, et al.
·
Radiation Oncology
Neoadjuvant short-course radiotherapy combined with CAPOX and PD-1 inhibitor for MSS/pMMR high-risk locally advanced colon cancer: A randomized, prospective, multicentre, phase II trial (TORCH-C).
2026
·
Hui Zhang
, Fan Xia
, et al.
·
Journal of Clinical Oncology
PDF
Supplementary Table S4 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
2025
·
Fan Xia
, Yajie Chen
, et al.
Supplement File 2_Protocol2 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
2025
·
Fan Xia
, Yajie Chen
, et al.
Data from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
2025
·
Fan Xia
, Yajie Chen
, et al.
Supplement File 1_Checklist1 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
2025
·
Fan Xia
, Yajie Chen
, et al.
Supplementary Table S3 from Organ Preservation via Immunotherapy-Based Total Neoadjuvant Therapy in Early Low Rectal Cancer (TORCH-E): A Multicenter, Open-label, Single-Arm, Phase II Study
2025
·
Fan Xia
, Yajie Chen
, et al.
485P A phase Ib study of cetuximab combined with fruquintinib in the previously treated RAS/BRAF wild-type metastatic colorectal cancer: The preliminary result of CEFRU study
2021
·
Y. LI
, X. Chen
, et al.
·
Annals of Oncology
PDF
Show more works
View as search
Works count:
12
Citation count:
17
H-index:
2
I10-index:
1
Year
Topic
Type